📣Predictors of Left Ventricular Systolic Dysfunction on mavacamten in oHCM (n=180): 12% developed LVSD (echo EF <50%) over ~58 wks; LBBB/ventricular pacing (57% vs 22%), history of AF (48% vs 24%) and LGE burden associated with LVSD💡💉doi.org/10.1016/j.yjca… @JCFINT #HCM #cvHCM
Daniele Massera
@danmassera
Hypertrophic Cardiomyopathy @nyulangone. Tweets are mine.
149 Following 395 Followers 57 Posts
Latest posts 5
🚨Mark your calendars! Join us Sept 12 at NYU for our Hypertrophic Cardiomyopathy Symposium — cutting-edge science, expert panels, and the latest in diagnosis & treatment. Don’t miss it! #NYUCardiology
Agenda highmarksce.com/nyumc/index.cf…
highmarksce.com/nyumc/Planners…
Agenda highmarksce.com/nyumc/index.cf…
highmarksce.com/nyumc/Planners…
Disopyramide for long-term treatment of obstructive #hcm? Check out our work looking at patients treated for ≥5 years at @nyulangone @LaheyHospital with 67% still on drug after ~7 years
@EthanRowin @MartinMaronMD
ahajournals.org/doi/full/10.11…
@EthanRowin @MartinMaronMD
ahajournals.org/doi/full/10.11…
🍝Eating before resting and 🏃stress echo unmasked left ventricular outflow obstruction ≥50 mmHg in 35% of #HCM patients believed to have no significant obstruction. Check out our new data in @JournalASEcho
#CardioTwitter #Echofirst @nyulangone
onlinejase.com/article/S0894-…
#CardioTwitter #Echofirst @nyulangone
onlinejase.com/article/S0894-…
Mitral Leaflet Shortening as an Ancillary Procedure in Obstructive Hypertrophic Cardiomyopathy - The Annals of Thoracic Surgery annalsthoracicsurgery.org/article/S0003-…